NHS England's siloed budget and its uncertain future
Obesity is on the rise in low- and middle-income countries, particularly in urban settings
The Turkish biopharma market offers many opportunities - if it can overcome its sustainability challenge
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation
The condition is still an unstoppable epidemic
Tighter regulations, more pricing controls and increased international competition will drive market improvements
But will the highly efficient market be hindered by the government price referencing system?
Cutting through the NICE value-based assessment consultation to find out what’s at stake
Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential
UK's MHRA gives its views on rep training, pharma advertising and social media
French authorities will expect robust health economic cases to be made for some drugs
EUnetHTA strengthens role in market access in EU
Ten per cent is not enough - simple estimates of the Canadian oncology market overlook a complex picture
Selling vaccines in the region places commercial considerations alongside humanitarian obligations
Assessing the opportunities and challenges for pharmaceutical companies entering the Russian market
From a nation in love with branded medicines to one reliant on generics
Russian lifestyles present a significant challenge to the country’s health services
How will health reforms, the tightening of regulations and the emergence of a domestic drug industry impact global pharmaceutical companies?
As the BRIC foundations become firmly established, where next – and how soon – for those pharma companies seeking to exploit the developing markets?
Healthcare reforms open up huge potential in the market to companies with a carefully tailored expansion strategy